| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
5-HT2B receptor; 5-HT2B antagonist-1 is a selective antagonist of the 5-HT2B receptor. The 5-HT2B receptor is a subtype of serotonin receptors involved in various physiological processes, including smooth muscle contraction, cardiovascular function, and cell proliferation. By blocking this receptor, the compound may offer therapeutic benefits in conditions like cancer and cardiovascular disease.
|
|---|---|
| ln Vitro |
5-HT2B antagonist-1 (compound 5g) exhibits sodium channel binding activity, as evidenced by its IC50 values, which vary from 12.6 to 57.5 μM [1]. Compound 1-e, also known as 5-HT2B antagonist-1, suppresses 5-HT2B receptor activation in the CHO-K1 cell line by less than 50% at 1 μM [3].
In vitro, 5-HT2B antagonist-1 suppresses 5-HT2B receptor activation in the CHO-K1 cell line by less than 50% at 1 μM. It also exhibits sodium channel binding activity with IC50 values ranging from 12.6 to 57.5 μM. This demonstrates its potent receptor antagonism and potential for multi-target interactions. |
| ln Vivo |
In rats with irritable bowel syndrome (IBS), oral gavage with 5-HT2B antagonist-1 (compound 15) at a dose of 30 mg/kg can considerably diminish visceral hypersensitivity [2].
In vivo, oral administration of 5-HT2B antagonist-1 at 30 mg/kg considerably diminishes visceral hypersensitivity in rats with irritable bowel syndrome (IBS). This confirms its oral bioavailability and efficacy in a disease model. It is used to study conditions characterized by 5-HT2B receptor signaling. |
| Enzyme Assay |
In vitro, receptor binding and functional assays are performed using CHO-K1 cells expressing the 5-HT2B receptor. Cells are treated with the compound, and receptor activation is measured. Sodium channel activity is assessed using electrophysiological or binding assays.
|
| Cell Assay |
For in vitro studies, CHO-K1 cells expressing the 5-HT2B receptor are cultured and treated with 5-HT2B antagonist-1. The compound is typically dissolved in DMSO. Receptor antagonism is measured by assessing the inhibition of 5-HT-induced signaling, such as calcium mobilization or inositol phosphate accumulation.
|
| Animal Protocol |
In vivo, the compound is administered orally to rat models of irritable bowel syndrome. The animals are treated with a dose of 30 mg/kg. Visceral hypersensitivity is then measured to assess the compound's efficacy.
|
| ADME/Pharmacokinetics |
5-HT2B antagonist-1 has a molecular weight of 444.61 and formula C22H28N4O2S2. It is an orally bioactive compound. It is soluble in DMSO (≥ 33.33 mg/mL) and water (~12.5 mg/mL). LogP is 5.1. Storage: Powder at -20°C for 3 years or at 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are not extensively documented. As a 5-HT2B antagonist, it may have effects on cardiovascular and gastrointestinal systems. The compound is for research use only. It should be handled with appropriate safety precautions.
|
| References |
|
| Additional Infomation |
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM. It is used to study diseases characterized by 5-HT2B receptor signaling. It is also known as compound WAY-388264-A.
|
| Molecular Formula |
C11H14BRN5
|
|---|---|
| Molecular Weight |
296.17
|
| Exact Mass |
444.165
|
| CAS # |
393129-91-4
|
| PubChem CID |
1276160
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
689
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(=CC=C(C=C1)Br)NC1NC(N=C(N=1)N)(C)C
|
| InChi Key |
VDTGYRUIQQDQTL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H28N4O2S2/c1-15-16(2)29-21-19(15)20(23-14-24-21)25-10-12-26(13-11-25)30(27,28)18-8-6-17(7-9-18)22(3,4)5/h6-9,14H,10-13H2,1-5H3
|
| Chemical Name |
4-[4-(4-tert-butylphenyl)sulfonylpiperazin-1-yl]-5,6-dimethylthieno[2,3-d]pyrimidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 33.33 mg/mL (~112.54 mM)
H2O : ~12.5 mg/mL (~42.21 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3764 mL | 16.8822 mL | 33.7644 mL | |
| 5 mM | 0.6753 mL | 3.3764 mL | 6.7529 mL | |
| 10 mM | 0.3376 mL | 1.6882 mL | 3.3764 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
